Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia

NCT ID: NCT02307201

Last Updated: 2017-02-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 1114 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2015-12-31

Brief Summary

There is no evidence that patients receiving magnesium sulfate before birth are required to maintain the drug for 24 hours. Therefore the investigators will have a randomized clinical study in patients with severe preeclampsia who have been treated with impregnation of magnesium sulphate and at least eight hours have received the drug before birth. If the patient agrees and signs the consent is randomized to: 1-receive sulfate for 24 hours postpartum as usual or, 2- not receiving the postpartum magnesium sulfate or other anticonvulsant drugs. This study can be conducted in 12 maternity latin america.

Detailed Description

The final treatment known for pre-eclampsia and eclampsia is the termination of pregnancy. However to prevent eclampsia in patients with severe pre-eclampsia has been demonstrated the effectiveness of magnesium sulfate. There are multiple studies that prove the effectiveness of magnesium sulfate to prevent eclampsia in patients with severe disorder of blood pressure during pregnancy. These studies used the drug before birth and continue after birth. Therefore the investigators can not conclude whether the administration just before pregnancy is sufficient to prevent seizure. If the cure or definitive treatment of pre-eclampsia is the interruption, did not seem necessary to justify the administration of drugs anti-eclampsia after birth. Obvious post delivery management with magnesium sulfate arises from the large number of postpartum eclampsia reported in many studies. It is unknown whether administration of magnesium sulfate for a minimum period before delivery, requires even keep the drug post partum.

In addition to magnesium sulfate postpartum, is necessary to maintain urinary catheter to monitoring the removal of magnesium sulfate; is usual to maintain the patient at all or almost all rest by monitoring sulfate and diuresis , this prevents a proper relationship mother and babe and even prevents breastfeeding during that period and is also known increased risk of secondary thromboembolism due to prolonged rest in the postpartum / caesarean section.Thus, maintain magnesium sulfate for 24 hours carries a higher cost, greater vigilance and some risks, without known real effect.

A randomized clinical study conducted by Belfort and colleagues and published in January 2003, where magnesium sulphate compared to nimodipine to prevent eclampsia in women with severe pre-eclampsia, showed interesting outcome. Such research analyzed 819 randomized patients in the nimodipine group and 831 in the magnesium sulfate group. Magnesium sulphate was better than Nimodipine in preventing eclampsia. Interestingly, the greater effectiveness of sulfate appears to prevent all eclampsia postpartum (9 vs 0) and obviously was used before the termination of pregnancy, however no difference compared with nimodipine in eclampsia before birth (12 vs 7).

There are two possible reasons for the non-appearance of postpartum eclampsia: 1- maintain postpartum magnesium sulfate, 2- dose 12-13 grams before birth disruption are sufficient to prevent eclampsia.

The MAGPIE study randomized 1335 postpartum patients (unused sulphate before delivery) using magnesium sulfate postpartum / cesarean (696 women) or placebo postpartum / cesarean (639 women), and found no significant difference in the amount of eclampsia . Thus, the use of magnesium sulfate for first time in the postpartum is not better to use a placebo. If the investigators combine the findings of eclampsia postpartum Belfort study and MAGPIE study is logical to think that the success of the Belfort study in the postpartum is not for the use of magnesium sulfate post delivery and not only due to the termination of pregnancy because there are postpartum eclampsia in the nimodipine group.

If the investigators consider unjustified use of magnesium sulfate postpartum, when maintained at least 8 hours before delivery, the investigators decided to make a non-inferiority randomized study.The investigators assume that using or not using magnesium sulfate during the postpartum prevents similar amount of postpartum eclampsia, if during pregnancy was used (impregnation and at least 8 hours before birth).

For all these reasons the investigators propose the following: A randomized trial is necessary where all those patients who received magnesium sulfate for at least 8 hours before birth (involves impregnation and maintenance 8 hours) will be randomized to two groups of study: 1- Continue magnesium sulfate for 24 hours and 2-not use magnesium sulfate or other anticonvulsant drug post delivery.

This study is planned in 12 maternity latin america

Conditions

Post Partum Severe Preeclampsia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Postpartum Magnesium sulfate

The patient will receive magnesium sulfate as usual for 24 hours postpartum

Group Type: EXPERIMENTAL

Magnesium Sulfate

Intervention Type: DRUG

The patient will receive magnesium sulfate for 24 hours postpartum

No postpartum treatment

The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Magnesium Sulfate

The patient will receive magnesium sulfate for 24 hours postpartum

Intervention Type: DRUG

Other Intervention Names

No postpartum treatment

Eligibility Criteria

Inclusion Criteria

• Severe preeclampsia or severe preeclampsia aggregated to chronic hypertension with > 24 weeks of gestation treated with 4-6 grams of magnesium sulfate for impregnation with a minimum of 8 hours continuous of magnesium sulfate before delivery
• The study begins to terminate pregnancy

Exclusion Criteria

• HELLP syndrome
• Eclampsia
• Renal insufficiency
• Diabetes mellitus
• Disease of collagen
• Heart disease

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 44 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Complejo Hospitalario Dr. Arnulfo Arias Madrid

OTHER

Sponsor Role: lead

Responsible Party

Paulino Vigil-De Gracia

MEDICAL DOCTOR, GYNECOLOGY AND OBSTETRIC

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Paulino Vigil De Gracia

Role: PRINCIPAL_INVESTIGATOR

Complejo Hospitalario Dr. Arnulfo Arias Madrid

Jack Ludmir, MD

Role: STUDY_CHAIR

School of medicine, Pennsylvania Hospital. University de Pennsylvania. Philadelphia

Locations

Hospital Materno Infantil san Lorezo de las Minas

Santo Domingo, Santo Domingo Province, Dominican Republic

Hospital Universitario Maternidad Nuestra señoa de Alta Gracia

Santo Domingo, Santo Domingo Province, Dominican Republic

Hospital Teodoro Maldonado De Guayaquil

Guayaquil, , Ecuador

Hospital Primero de Mayo

San Salvador, , El Salvador

Hospital Jose Domingo De Obaldia

Chiriquí, Chiriquí Province, Panama

Complejo Hospitalario Caja de Seguro Social

Panama City, Provincia de Panamá, Panama

Hospital Santo Tomás

Panama City, Provincia de Panamá, Panama

Hospital Regional de Cojamarca, Perú,

Cajamarca, Cajamarca Department, Peru

Instituto Materno perinatal, Maternidad de Lima

Lima, Lima Province, Peru

Countries

Dominican Republic; Ecuador; El Salvador; Panama; Peru

References

Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003 Jan 23;348(4):304-11. doi: 10.1056/NEJMoa021180.

Reference Type: BACKGROUND

PMID: 12540643 (View on PubMed)

Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002 Jun 1;359(9321):1877-90. doi: 10.1016/s0140-6736(02)08778-0.

Reference Type: RESULT

PMID: 12057549 (View on PubMed)

Other Identifiers

complejoh

Identifier Type: -

Identifier Source: org_study_id